SAPB Trial Tests Whether Regional Analgesia Can Improve Recovery After MIDCABG
A single-center randomized trial in China will examine whether an ultrasound-guided serratus anterior plane block can improve early recovery after minimally invasive coronary artery bypass grafting. The study is designed around a problem that cardiac surgeons and anesthesiologists know well: minimally invasive access reduces surgical trauma, but it does not eliminate the chest wall pain created when ribs are spread and intercostal nerves are irritated during the procedure.
That pain can be more than a comfort issue. Postoperative splinting limits deep breathing and coughing, slows mobilization, and can complicate the early recovery period in a patient population already vulnerable to pulmonary problems and prolonged convalescence. In a setting such as MIDCABG, where the incision is smaller but the mechanics of the operation still stress the thoracic wall, the promise of regional anesthesia is straightforward: blunt nociceptive input before it fuels a cascade of opioid exposure, immobility, and delayed recovery.
Why the Serratus Plane Matters in a Small Left Chest Incision
The study centers on the lateral branches of the intercostal nerves, which are a major pathway for anterior-lateral chest wall pain. The serratus anterior plane block deposits local anesthetic into the fascial plane around the serratus anterior muscle under ultrasound guidance, aiming to intercept those signals before they reach the central nervous system. In practical terms, that may spare the patient from the diffuse pain that often follows left thoracic entry for coronary bypass, especially when the chest wall has been retracted and the intercostal space has been manipulated.
The protocol uses ropivacaine for the active arm and normal saline for the placebo arm. Both groups receive general anesthesia, and the block is performed after induction and before incision, which positions the intervention as a preventive strategy rather than a rescue maneuver. Preventive analgesia is biologically appealing in cardiac surgery because early nociceptive blockade may reduce central sensitization and lower the need for opioid rescue during the first 72 hours, when pain can be especially disruptive.
Opioid-heavy recovery remains the default in many cardiac settings, but it carries familiar costs: nausea, vomiting, respiratory depression, and urinary retention. Those adverse effects can interfere with mobilization and pulmonary hygiene, two priorities that matter immediately after bypass surgery. By building a regional block into the multimodal plan, the trial is asking whether a simpler fascial plane technique can deliver enough analgesia to support faster, cleaner recovery without the complexity of epidural or paravertebral approaches.
Trial Design Focuses on Recovery Quality, Not Pain Alone
The study is a randomized, parallel-assignment, double-blind trial. The masking strategy covers both participants and outcome assessors, a design choice that helps preserve interpretability when the endpoint includes patient-reported recovery. The estimated enrollment is 168 adults, and eligibility runs from age 18 to 80 years. Participants must be scheduled for elective MIDCABG, able to complete the 15-item Quality of Recovery questionnaire, and willing to provide written informed consent.
Several exclusions narrow the population to patients who can safely undergo the block and reliably report their recovery experience. Patients with ASA physical status class IV or higher, allergy to ropivacaine, coagulation disorders, infection at the puncture site, cognitive impairment, emergency surgery, or severe hepatic or renal insufficiency are excluded. Those criteria matter because the trial is testing a technique that has to be both technically feasible and clinically relevant in a carefully selected surgical cohort.
The primary endpoint is the QoR-15 score, measured on postoperative days 1, 2, and 3, corresponding to 24, 48, and 72 hours after surgery. The questionnaire spans pain, physical comfort, physical independence, psychological support, and emotional state, producing a total score from 0 to 150, with higher values indicating better recovery quality. In cardiac surgery, a composite recovery measure is often more meaningful than pain intensity alone because it captures how analgesia affects movement, sleep, function, and the lived experience of the immediate postoperative period.
A Direct Test of Whether Blockade Changes the Recovery Trajectory
The study’s logic is anchored in a simple clinical question: if pain transmission from the left chest wall is interrupted at the source, does the entire recovery course improve? A regional block that is effective at the bedside should reduce pain during the first three days, but the more important issue is whether that reduction translates into better functional recovery, not merely a lower number on a pain scale.
For minimally invasive bypass surgery, this distinction is especially important. MIDCABG was developed to reduce surgical trauma, blood loss, and recovery time, yet the chest wall pain generated by the access route can still undermine those advantages. When the incision hurts enough to limit coughing and mobility, the operation’s minimally invasive label does not automatically translate into a smoother postoperative course. The trial is built to measure exactly that gap between technical minimalism and postoperative reality.
The choice of an ultrasound-guided fascial plane block also reflects changing regional anesthesia practice. Unlike neuraxial techniques, which can be more difficult to place and more complicated to manage in anticoagulated cardiac patients, a serratus plane block is relatively accessible and may fit more naturally into operating room workflows. Its appeal is not abstract; it is tied to the specific constraints of coronary bypass patients, where bleeding risk, operative efficiency, and postoperative respiratory function all compete for attention.
What This Trial Can and Cannot Answer
Because the study is not yet recruiting, its value is prospective rather than evidentiary. It cannot yet claim benefit, and it cannot yet establish whether ropivacaine-based SAPB will outperform saline in a way that changes routine cardiac anesthesia practice. The protocol also remains single-center, which can sharpen internal consistency while limiting how broadly the findings can be applied to other surgical programs with different techniques, patient mixes, or perioperative pathways.
Still, the endpoint selection gives the trial a clinically grounded focus. A block that truly improves recovery should make itself visible across multiple dimensions of the QoR-15 instrument, not just through a transient dip in pain scores. If the intervention succeeds, it would support a cleaner multimodal pathway for postoperative pain control after MIDCABG, with less reliance on systemic opioids and more attention to the mechanics of breathing, mobilization, and early independence.
Even without results, the protocol reflects a broader shift in cardiac anesthesia: pain control is no longer judged solely by whether a patient survives the operation, but by whether the patient can recover with less physiologic friction in the first critical days after surgery. This trial will test whether a targeted chest wall block can deliver that result in a procedure where the incision is small, yet the pain can still be substantial.